{
    "id": 18006,
    "fullName": "EIF3E - RSPO2",
    "impact": "fusion",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "EIF3E-RSPO2 results from the fusion of EIF3E and RSPO2, resulting in overexpression of Rspo2 and activation of the Wnt signaling pathway (PMID: 22895193). EIF3E-RSPO2 has been identified in colorectal cancer (PMID: 30916365).",
            "references": [
                {
                    "id": 4597,
                    "pubMedId": 22895193,
                    "title": "Recurrent R-spondin fusions in colon cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22895193"
                },
                {
                    "id": 16983,
                    "pubMedId": 30916365,
                    "title": "EIF3E-RSPO2 and PIEZO1-RSPO2 fusions in colorectal traditional serrated adenoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30916365"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 3646,
        "geneSymbol": "EIF3E",
        "terms": [
            "EIF3E",
            "eIF3-p46",
            "EIF3-P48",
            "EIF3S6",
            "INT6"
        ]
    },
    "variant": "EIF3E - RSPO2",
    "createDate": "02/15/2016",
    "updateDate": "03/09/2020",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        {
            "gene": {
                "id": 340419,
                "geneSymbol": "RSPO2",
                "terms": [
                    "RSPO2",
                    "CRISTIN2",
                    "HHRRD",
                    "TETAMS2"
                ]
            }
        }
    ],
    "evidence": [
        {
            "id": 5028,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed human cells expressing EIF3E-RSPO2 were sensitive to ETC-159, resulting in decreased Wnt/Beta-catenin signaling (PMID: 26257057).",
            "molecularProfile": {
                "id": 18335,
                "profileName": "EIF3E - RSPO2"
            },
            "therapy": {
                "id": 3534,
                "therapyName": "ETC-159",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4598,
                    "pubMedId": 26257057,
                    "title": "Wnt addiction of genetically defined cancers reversed by PORCN inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26257057"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5031,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, IWR-1 treatment resulted in a synergistic effect when combined with Afinitor (everolimus), inducing apoptosis of malignant peripheral nerve sheath tumor cells harboring EIF3E-RSPO2 (PMID: 23535903).",
            "molecularProfile": {
                "id": 18335,
                "profileName": "EIF3E - RSPO2"
            },
            "therapy": {
                "id": 3733,
                "therapyName": "Everolimus + IWR-1",
                "synonyms": null
            },
            "indication": {
                "id": 5940,
                "name": "malignant peripheral nerve sheath tumor",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4843,
                    "pubMedId": 23535903,
                    "title": "Canonical Wnt/\u03b2-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23535903"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5030,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, malignant peripheral nerve sheath tumor cells harboring EIF3E-RSPO2 were sensitive to IWR-1 (PMID: 23535903).",
            "molecularProfile": {
                "id": 18335,
                "profileName": "EIF3E - RSPO2"
            },
            "therapy": {
                "id": 2455,
                "therapyName": "IWR-1",
                "synonyms": null
            },
            "indication": {
                "id": 5940,
                "name": "malignant peripheral nerve sheath tumor",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4843,
                    "pubMedId": 23535903,
                    "title": "Canonical Wnt/\u03b2-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23535903"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5032,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, XAV939 treatment resulted in a synergistic effect when combined with Afinitor (everolimus), inducing apoptosis of malignant peripheral nerve sheath tumor cells harboring EIF3E-RSPO2 (PMID: 23535903).",
            "molecularProfile": {
                "id": 18335,
                "profileName": "EIF3E - RSPO2"
            },
            "therapy": {
                "id": 3734,
                "therapyName": "Everolimus + XAV939",
                "synonyms": null
            },
            "indication": {
                "id": 5940,
                "name": "malignant peripheral nerve sheath tumor",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4843,
                    "pubMedId": 23535903,
                    "title": "Canonical Wnt/\u03b2-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23535903"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5029,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, malignant peripheral nerve sheath tumor cells harboring EIF3E-RSPO2 were sensitive to XAV939 (PMID: 23535903).",
            "molecularProfile": {
                "id": 18335,
                "profileName": "EIF3E - RSPO2"
            },
            "therapy": {
                "id": 1732,
                "therapyName": "XAV939",
                "synonyms": null
            },
            "indication": {
                "id": 5940,
                "name": "malignant peripheral nerve sheath tumor",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4843,
                    "pubMedId": 23535903,
                    "title": "Canonical Wnt/\u03b2-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23535903"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 18335,
            "profileName": "EIF3E - RSPO2",
            "profileTreatmentApproaches": [
                {
                    "id": 8139,
                    "name": "WNT Inhibitor",
                    "profileName": "EIF3E - RSPO2"
                },
                {
                    "id": 8140,
                    "name": "Tankyrase Inhibitor",
                    "profileName": "EIF3E - RSPO2"
                }
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}